| Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy MG Lechner, SS Karimi, K Barry-Holson, TE Angell, KA Murphy, ... Journal of immunotherapy 36 (9), 477-489, 2013 | 393 | 2013 |
| Performance of a genomic sequencing classifier for the preoperative diagnosis of cytologically indeterminate thyroid nodules KN Patel, TE Angell, J Babiarz, NM Barth, T Blevins, QY Duh, ... JAMA surgery 153 (9), 817-824, 2018 | 325 | 2018 |
| The influence of patient age on thyroid nodule formation, multinodularity, and thyroid cancer risk N Kwong, M Medici, TE Angell, X Liu, E Marqusee, ES Cibas, JF Krane, ... The Journal of Clinical Endocrinology & Metabolism 100 (12), 4434-4440, 2015 | 243 | 2015 |
| MHC Class I Loss Is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer That Is Reversed by Interferon and Selumetinib Treatment In Vitro TE Angell, MG Lechner, JK Jang, JS LoPresti, AL Epstein Clinical Cancer Research 20 (23), 6034-6044, 2014 | 153 | 2014 |
| Clinical features and hospital outcomes in thyroid storm: a retrospective cohort study TE Angell, MG Lechner, CT Nguyen, VL Salvato, JT Nicoloff, JS LoPresti The Journal of Clinical Endocrinology & Metabolism 100 (2), 451-459, 2015 | 142 | 2015 |
| Survival Signals and Targets for Therapy in Breast Implant–Associated ALK− Anaplastic Large Cell Lymphoma MG Lechner, C Megiel, CH Church, TE Angell, SM Russell, RB Sevell, ... Clinical Cancer Research 18 (17), 4549-4559, 2012 | 136 | 2012 |
| Immune cell infiltration patterns and survival in head and neck squamous cell carcinoma SM Russell, TE Angell, MG Lechner, DJ Liebertz, AJ Correa, UK Sinha, ... Head & neck oncology 5 (3), 24, 2013 | 131 | 2013 |
| BRAFV600E in Papillary Thyroid Carcinoma Is Associated with Increased Programmed Death Ligand 1 Expression and Suppressive Immune Cell Infiltration TE Angell, MG Lechner, JK Jang, AJ Correa, JS LoPresti, AL Epstein Thyroid 24 (9), 1385-1393, 2014 | 126 | 2014 |
| Bethesda categorization of thyroid nodule cytology and prediction of thyroid cancer type and prognosis X Liu, M Medici, N Kwong, TE Angell, E Marqusee, MI Kim, PR Larsen, ... Thyroid 26 (2), 256-261, 2016 | 100 | 2016 |
| Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features Accounts for More Than Half of “Carcinomas” Harboring RAS Mutations VA Paulson, P Shivdasani, TE Angell, ES Cibas, JF Krane, NI Lindeman, ... Thyroid 27 (4), 506-511, 2017 | 85 | 2017 |
| Independent comparison of the Afirma genomic sequencing classifier and gene expression classifier for cytologically indeterminate thyroid nodules TE Angell, HT Heller, ES Cibas, JA Barletta, MI Kim, JF Krane, ... Thyroid 29 (5), 650-656, 2019 | 81 | 2019 |
| The variable phenotype and low-risk nature of RAS-positive thyroid nodules M Medici, N Kwong, TE Angell, E Marqusee, MI Kim, MC Frates, ... BMC medicine 13, 1-9, 2015 | 81 | 2015 |
| Circulating myeloid-derived suppressor cells predict differentiated thyroid cancer diagnosis and extent TE Angell, MG Lechner, AM Smith, SE Martin, SG Groshen, DR Maceri, ... Thyroid 26 (3), 381-389, 2016 | 74 | 2016 |
| Differences in thyroid nodule cytology and malignancy risk between children and adults CE Cherella, TE Angell, DM Richman, MC Frates, CB Benson, FD Moore, ... Thyroid 29 (8), 1097-1104, 2019 | 73 | 2019 |
| Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes SC Baca, KS Wong, KC Strickland, HT Heller, MI Kim, JA Barletta, ... Cancer Cytopathology 125 (5), 313-322, 2017 | 69 | 2017 |
| The impact of Hashimoto thyroiditis on thyroid nodule cytology and risk of thyroid cancer N Silva de Morais, J Stuart, H Guan, Z Wang, ES Cibas, MC Frates, ... Journal of the Endocrine Society 3 (4), 791-800, 2019 | 65 | 2019 |
| Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma TE Angell, L Min, TJ Wieczorek, FS Hodi Genes & diseases 5 (1), 46-48, 2018 | 62 | 2018 |
| Noninvasive follicular variant of papillary thyroid carcinoma and the Afirma gene-expression classifier KS Wong, TE Angell, KC Strickland, EK Alexander, ES Cibas, JF Krane, ... Thyroid 26 (7), 911-915, 2016 | 62 | 2016 |
| High-dose biotin treatment for secondary progressive multiple sclerosis may interfere with thyroid assays A Minkovsky, MN Lee, M Dowlatshahi, TE Angell, LS Mahrokhian, ... AACE clinical case reports 2 (4), e370-e373, 2016 | 59 | 2016 |
| A cohort analysis of clinical and ultrasound variables predicting cancer risk in 20,001 consecutive thyroid nodules TE Angell, R Maurer, Z Wang, MI Kim, CA Alexander, JA Barletta, ... The Journal of Clinical Endocrinology & Metabolism 104 (11), 5665-5672, 2019 | 56 | 2019 |
